source
- Roche halts lupus T-cell engager RG6382 development after early trial reviewRoche announced it is stopping work on RG6382, a bispecific T-cell engager targeting CD19 and CD3, which was being tested in a phase‑1 study in patients with systemic lupus erythematosus (SLE). Th…
- FDA approves Johnson & Johnson's Ottava robotic system for multiple soft-tissue surgeriesFDA cleared Johnson & Johnson's Ottava robotic surgical system, marking its entry into the market. The clearance covers a range of soft-tissue procedures such as gastric bypass, gastrectomy, chole…